These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

567 related items for PubMed ID: 11607812

  • 1. Translocations involving c-myc and c-myc function.
    Boxer LM, Dang CV.
    Oncogene; 2001 Sep 10; 20(40):5595-610. PubMed ID: 11607812
    [Abstract] [Full Text] [Related]

  • 2. Role of myc amplification and overexpression in cell growth, differentiation and death.
    Koskinen PJ, Alitalo K.
    Semin Cancer Biol; 1993 Feb 10; 4(1):3-12. PubMed ID: 8448376
    [Abstract] [Full Text] [Related]

  • 3. Iron specific growth inhibition of Burkitt's lymphoma cells in vitro, associated with a decrease in translocated c-myc expression.
    Habel ME, Lemieux R, Jung D.
    J Cell Physiol; 2005 Apr 10; 203(1):277-85. PubMed ID: 15468060
    [Abstract] [Full Text] [Related]

  • 4. Function of the c-Myc oncogenic transcription factor.
    Dang CV, Resar LM, Emison E, Kim S, Li Q, Prescott JE, Wonsey D, Zeller K.
    Exp Cell Res; 1999 Nov 25; 253(1):63-77. PubMed ID: 10579912
    [Abstract] [Full Text] [Related]

  • 5. The proto-oncogene c-myc in hematopoietic development and leukemogenesis.
    Hoffman B, Amanullah A, Shafarenko M, Liebermann DA.
    Oncogene; 2002 May 13; 21(21):3414-21. PubMed ID: 12032779
    [Abstract] [Full Text] [Related]

  • 6. Epstein-Barr virus nuclear antigen 2 is a transcriptional suppressor of the immunoglobulin mu gene: implications for the expression of the translocated c-myc gene in Burkitt's lymphoma cells.
    Jochner N, Eick D, Zimber-Strobl U, Pawlita M, Bornkamm GW, Kempkes B.
    EMBO J; 1996 Jan 15; 15(2):375-82. PubMed ID: 8617212
    [Abstract] [Full Text] [Related]

  • 7. The Myc oncoprotein as a therapeutic target for human cancer.
    Vita M, Henriksson M.
    Semin Cancer Biol; 2006 Aug 15; 16(4):318-30. PubMed ID: 16934487
    [Abstract] [Full Text] [Related]

  • 8. c-Myc inhibits Ras-mediated differentiation of pheochromocytoma cells by blocking c-Jun up-regulation.
    Vaqué JP, Fernández-García B, García-Sanz P, Ferrandiz N, Bretones G, Calvo F, Crespo P, Marín MC, León J.
    Mol Cancer Res; 2008 Feb 15; 6(2):325-39. PubMed ID: 18314492
    [Abstract] [Full Text] [Related]

  • 9. Functions of myc:max in the control of cell proliferation and tumorigenesis.
    Hurlin PJ, Dezfouli S.
    Int Rev Cytol; 2004 Feb 15; 238():183-226. PubMed ID: 15364199
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of the translocated c-myc in Burkitt's lymphoma by a PNA complementary to the E mu enhancer.
    Cutrona G, Carpaneto EM, Ponzanelli A, Ulivi M, Millo E, Scarfì S, Roncella S, Benatti U, Boffa LC, Ferrarini M.
    Cancer Res; 2003 Oct 01; 63(19):6144-8. PubMed ID: 14559793
    [Abstract] [Full Text] [Related]

  • 11. Mnt takes control as key regulator of the myc/max/mxd network.
    Wahlström T, Henriksson M.
    Adv Cancer Res; 2007 Oct 01; 97():61-80. PubMed ID: 17419941
    [Abstract] [Full Text] [Related]

  • 12. c-myc Suppression in Burkitt's lymphoma cells.
    Simonsson T, Henriksson M.
    Biochem Biophys Res Commun; 2002 Jan 11; 290(1):11-5. PubMed ID: 11779125
    [Abstract] [Full Text] [Related]

  • 13. MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells.
    Sampson VB, Rong NH, Han J, Yang Q, Aris V, Soteropoulos P, Petrelli NJ, Dunn SP, Krueger LJ.
    Cancer Res; 2007 Oct 15; 67(20):9762-70. PubMed ID: 17942906
    [Abstract] [Full Text] [Related]

  • 14. Decreased tumorigenicity of c-Myc-transformed fibroblasts expressing active USF2.
    Choe C, Chen N, Sawadogo M.
    Exp Cell Res; 2005 Jan 01; 302(1):1-10. PubMed ID: 15541720
    [Abstract] [Full Text] [Related]

  • 15. Kinetics of myc-max-mad gene expression during hepatocyte proliferation in vivo: Differential regulation of mad family and stress-mediated induction of c-myc.
    Mauleon I, Lombard MN, Muñoz-Alonso MJ, Cañelles M, Leon J.
    Mol Carcinog; 2004 Feb 01; 39(2):85-90. PubMed ID: 14750213
    [Abstract] [Full Text] [Related]

  • 16. Low molecular weight inhibitors of Myc-Max interaction and function.
    Yin X, Giap C, Lazo JS, Prochownik EV.
    Oncogene; 2003 Sep 18; 22(40):6151-9. PubMed ID: 13679853
    [Abstract] [Full Text] [Related]

  • 17. Cancer therapeutics: targeting the dark side of Myc.
    Ponzielli R, Katz S, Barsyte-Lovejoy D, Penn LZ.
    Eur J Cancer; 2005 Nov 18; 41(16):2485-501. PubMed ID: 16243519
    [Abstract] [Full Text] [Related]

  • 18. Omomyc, a potential Myc dominant negative, enhances Myc-induced apoptosis.
    Soucek L, Jucker R, Panacchia L, Ricordy R, Tatò F, Nasi S.
    Cancer Res; 2002 Jun 15; 62(12):3507-10. PubMed ID: 12067996
    [Abstract] [Full Text] [Related]

  • 19. c-Myc creates an activation loop by transcriptionally repressing its own functional inhibitor, hMad4, in young fibroblasts, a loop lost in replicatively senescent fibroblasts.
    Marcotte R, Chen JM, Huard S, Wang E.
    J Cell Biochem; 2005 Dec 01; 96(5):1071-85. PubMed ID: 16167342
    [Abstract] [Full Text] [Related]

  • 20. The c-myc promoter: still MysterY and challenge.
    Wierstra I, Alves J.
    Adv Cancer Res; 2008 Dec 01; 99():113-333. PubMed ID: 18037408
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.